Table 4.
Summary of the characteristics of PNI, ALI, NLDA, and HALP in clinical studies.
| Parameter | Participants’ conditions | Cut-off value | Low/ High(N) | Outcome | AUC | Clinical findings | Reference |
|---|---|---|---|---|---|---|---|
| PNI | Patients with NSCLC | 49.5 | 69/69 | OS | – | PNI is an independent prognostic marker. | [45] |
| Patients with completely resected NSCLC | 50 | 149/241 | OS | 0.63 | PNI is an independent prognostic marker. | [52] | |
| Elderly (aged > 75 years) patients with completely resected NSCLC | 49.6 | 146/126 | OS | 0.532 | PNI is an independent prognostic marker. | [53] | |
| Patients with NSCLC underwent radical surgery | 52 | 912/504 | OS | – | Higher PNI in NSCLC patients suggests a favourable prognosis. | [54] | |
| Patients with completely resected NSCLC | 48 | 46/202 | OS, RFS | – | PNI is an independent prognostic marker. | [55] | |
| Patients with completely resected NSCLC | 45/50 | 57/134/324 | OS | – | PNI is an independent prognostic marker. | [56] | |
| Patients with NSCLC underwent open thoracotomy for curative resection | 50 | 285/726 | OS, RFS | 0.727 | PNI was associated with postoperative pulmonary complications and long-term outcomes. | [57] | |
| Patients with NSCLC underwent surgical pulmonary resection and receive neoadjuvant therapy | 46.810 | 37/73 | OS, RFS | 0.628 | PNI is an independent prognostic marker. | [58] | |
| Patients with NSCLC received adjuvant chemotherapy | 50 | 54/52 | RFS | – | PNI is an independent prognostic marker. | [59] | |
| Patients with NSCLC treated with EGFR TKI | 45 | 177/453 | OS, PFS | – | Pre-treatment nutritional status is a prognostic marker. | [60] | |
| Patients with NSCLC treated with ICIs | 45.5 | 52/50 | OS, PFS | 0.694 | PNI is an independent prognostic marker. | [62] | |
| Patients with NSCLC underwent curative radiotherapy | 45.45 | – | OS | 0.666 | PNI is an independent prognostic marker. | [63] | |
| Patients with aNSCLC treated with PD-1 inhibitors | 45 | 47/55 | OS, PFS | – | PNI may be a useful predictive marker of clinical outcomes and irAEs. | [64] | |
| Patients with advanced NSCLC treated with platinum-based chemotherapeutics | 52.525 | 54/45 | OS, PFS | – | PNI is an independent prognostic marker. | [65] | |
| Patients with recurrence NSCLC after complete pulmonary resection who received ICI monotherapy during the therapeutic course | 50 | – | PFS | – | PNI is an independent prognostic marker. | [66] | |
| Patients with aNSCLC treated with PD-1 inhibitors | 46.05 | 53/70 | OS, PFS | 0.780 | PNI was an independent predictor of early progression and survival outcomes. | [67] | |
| Patients with metastatic or recurrent ALK-positive NSCLC received first-line alectinib | 40 | 11/31 | PFS | – | PNI is important in predicting, which reflect the nutritional status of the host | [68] | |
| Patients in stage IA-IIIB with NSCLC underwent chest surgery | 47 | 193/282 | OS, RFS | 0.62 | PNI has high predictive values for postoperative complications and survival. | [70] | |
| Patients with bone mNSCLC without any anti-tumor therapy | 54.5 | 154/105 | OS | – | PNI is an independent prognostic marker. | [71] | |
| patients in stage IIIB/IV with NSCLC | 50 | 179/136 | OS | – | PNI is an independent prognostic marker. | [72] | |
| Patients with aNSCLC | 46.1 | 67/116 | OS | 0.55 | Nutritional status is an important prognostic factor. | [73] | |
| Patients with mNSCLC treated with first-line chemotherapy | 46.7 | 184/149 | OS, PFS | 0.617 | PNI is an independent prognostic marker. | [74] | |
| Patients in stage IIIB with NSCLC | 40.5 | 190/168 | OS, PFS, LPFS | 0.841 | PNI is an independent prognostic marker. | [75] | |
| Patients with aNSCLC | 38.4 | 52/108 | OS, PFS | 0.69 | PNI is an independent prognostic marker. | [76] | |
| ALI | Patients with mNSCLC | 18 | 83/90 | OS, PFS | 0.67 | ALI is an independent prognostic marker. | [47] |
| Patients with mNSCLC | 23.2 | 21/20 | OS, PFS | – | ALI is an independent prognostic marker. | [78] | |
| Patients in stage IV with NSCLC | 18 | 38/74 | OS | – | ALI is an independent prognostic marker. | [79] | |
| Patients with aNSCLC initiated nivolumab treatment | 18 | 69/128 | PFS | – | ALI is an independent prognostic marker. | [80] | |
| Patients with mNSCLC received complete first-line treatment with chemotherapy | 11 | 19/90 | OS, PFS | 0.52 | ALI is associated with survival. | [81] | |
| Patients with NSCLC received complete resection | 37.66 | 121/220 | OS | 0.681 | ALI is an independent prognostic marker. | [82] | |
| Patients with NSCLC underwent VATS | 41.20 | 125/214 | OS | 0.324 | ALI is an independent prognostic marker. | [83] | |
| Patients in stage IA with NSCLC underwent lung resection | 22.2 | 18/148 | OS, RFS | 0.610 | ALI is an independent prognostic marker. | [85] | |
| Patients with early-stage NSCLC received VATS pulmonary resection as their only therapy | 50 | 155/137 | OS, DFS | – | ALI is an independent prognostic marker. | [86] | |
| Patients with NSCLC treated with nivolumab | 18 | – | PFS | – | A high ALI was predictive of better PFS in patients with poor performance status. | [87] | |
| Patients with mNSCLC | 32.6 | 191/127 | OS | – | ALI is an independent prognostic marker. | [88] | |
| NLDA | IV stage NSCLC patients | 0.15 | 32/12 | OS | 0.7 | NLDA is an independent prognostic marker. | [49] |
| HALP | Patients with NSCLC underwent radical lung cancer resection | 48 | 99/139 | OS | 0.666 | HALP is an independent prognostic marker. | [51] |
NSCLC: non-small cell lung cancer; aNSCLC: advanced non-small cell lung cancer; mNSCLC: metastatic non-small cell lung cancer; LA-NSCLC: locally advanced non-small cell lung cancer; TKI: tyrosine kinase inhibitor; PD-1: programmed cell death protein‑1; ICI: immune checkpoint inhibitor; irAE: immune-related adverse event; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PFS: progression-free survival; LPFS: local progression-free survival; DFS: disease-free survival; RFS: relapse-free survival; VATS: video-assisted thoracic surgery; N: number of patients.